National   

Novartis case: arguments end

Special Correspondent

CHENNAI: Arguments on the petitions filed by Novartis AG, challenging the Constitutional validity of Section 3(d) of the Patents (Amendment) Act 2005 concluded before a Division Bench of the Madras High Court on Wednesday.

The Bench, comprising Justices R. Balasubramanian and Prabha Sridevan, however, commenced hearing on the statutory appeal of the company against the rejection of its application to patent beta crystalline form of imatinib mesylate, sold under the brand name Gleevec/Glivec.

While senior advocate P.S. Raman wound up the arguments, counsel for Cipla, Sun Pharmaceuticals and the Indian Pharmaceutical Alliance A. Ramesh Kumar, said he would file written submissions before the court.

Printer friendly page  
Send this article to Friends by E-Mail

Stories in this Section

BJP describes U.P. poll survey as `trash'
Apex court order opposed
Apex court ruling on divorce
Azad: do not politicise troops reduction issue
Interim report only after consensus: Nanavati
PDP postpones meeting
Rs. 13,000-crore package in Gujarat
Poor power supply to rural areas
Scientists discover two yeast species
``Talks on sovereignty out of question''
Jayalalithaa lawyer's stand on lands
Congress: we'll do exceptionally well
Order in Amitabh case put off to April 4
U.S. honour for Kalam
Novartis case: arguments end
Nip LTTE's air power: Swamy
10-day jail for Marathi editor recommended

Copyright © 2007, The Hindu. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu